- This event has passed.
2021 Alaska Pharmacy Residency Grand Rounds
When: Wednesday, May 19, 2021, 6:00 – 8:00 pm
Where: In-Person or Live Via Zoom (Link Below)
UAA/ISU Doctor of Pharmacy Program Facility, Professional Studies Building–Room 103, 2533 Providence Drive, Anchorage
Join Zoom Meeting: https://isu.zoom.us/j/86707883987?pwd=ekFtU0hES1pDNWErVkJUMDBMQ3BKdz09
What: The AKPhA Academy of Health-System Pharmacy is hosting this event, moderated by Academy Chair Angharad Ratliff of the UAA/ISU Doctor of Pharmacy Program. Members and Non-Members in Alaska are invited to attend, so mark your calendars, invite a friend and join us May 19th!
CPE Credit: This event will be accredited by AKPhA for up to 2.0 Hours. Credit will be awarded upon receipt of an online evaluation and reported to CPE Monitor within 60 days. Participants are to complete the evaluation using THIS LINK and submit by midnight, Friday, May 21st to receive credit. AKPhA is accredited by the Accreditation Council for Pharmacy Education as a provider of Continuing Pharmacy Education.
Target Audience: Pharmacists
UAN: 0139-0000-21-201-L01-P, Knowledge-based Activity
At the completion of this activity, the participant will be able to:
- Describe residency research projects completed in Alaska
- Identify potential projects or collaboration among health-systems based upon research conducted by pharmacy residents.
Moderator: Angharad Ratliff, PharmD, BCCCP, BCPS
Clinical Assistant Professor, UAA/ISU Doctor of Pharmacy Program
Presenters & Topics
Corrie Black, “Pre-post implementation impact assessment of a PCR blood culture identification panel on ASP outcomes”
Taylor Goree, “Impact of a granulocyte colony-stimulating factor (GCSF) guideline on appropriate use and expenditures – a comparative retrospective analysis”
Jessica Hiney, “Clinical, financial, and practical considerations for biosimilar use at an Alaska Native Hospital”
Tiffany Ma, “Implementation of the Aging Well initiative through the Nuka System of Care”
Andrew Zwerlein, “Pharmacist Intervention Impact on Medication Dosing Using an Obesity Dosing Guideline”